Evidence map›Paper›PMID 37333688›Full record

ArticleLancet regional health. Americas2023

Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study.

Katherine Adams, John J Riddles, Elizabeth A K Rowley, Shaun J Grannis, Manjusha Gaglani, Bruce Fireman, Emily Hartmann, Allison L Naleway, Edward Stenehjem, Alexandria Hughes and 27 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lancet regional health. Americas, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Trial
  2. Fast Track Intervention Effects and Mechanisms of Action Through Established Adulthood.Prevention science : the official journal of the Society for Prevention Research · 2025
    Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

37 authors at 14 institutions in 1 country.

Katherine AdamsInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
John J RiddlesWestat, Rockville, MD, USA.
Elizabeth A K RowleyWestat, Rockville, MD, USA.
Shaun J GrannisCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA.
Manjusha GaglaniBaylor Scott & White Health, Temple, TX, USA.
Bruce FiremanKaiser Permanente Vaccine Study Center, Kaiser Permanente Northern California Division of Research, Oakland, CA, USA.
Emily HartmannPaso del Norte Health Information Exchange (PHIX), El Paso, TX, USA.
Allison L NalewayKaiser Permanente Center for Health Research, Portland, OR, USA.
Edward StenehjemDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, UT, USA.
Alexandria HughesWestat, Rockville, MD, USA.
Alexandra F DaltonInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Karthik NatarajanDepartment of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.
Kristin DascombDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, UT, USA.
Chandni RaiyaniBaylor Scott & White Health, Temple, TX, USA.
Stephanie A IrvingKaiser Permanente Center for Health Research, Portland, OR, USA.
Chantel Sloan-AagardPaso del Norte Health Information Exchange (PHIX), El Paso, TX, USA.
Anupam B KharbandaChildren's Minnesota, Minneapolis, MN, USA.
Malini B DeSilvaHealthPartners Institute, Minneapolis, MN, USA.
Brian E DixonCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA.
Toan C OngSchool of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Jean KellerWestat, Rockville, MD, USA.
Monica DickersonInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Nancy GriselDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, UT, USA.
Kempapura MurthyBaylor Scott & White Health, Temple, TX, USA.
Juan NanezPaso del Norte Health Information Exchange (PHIX), El Paso, TX, USA.
William F FadelCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA.
Sarah W BallWestat, Rockville, MD, USA.
Palak PatelInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Julie ArndorferDivision of Infectious Diseases and Clinical Epidemiology, Intermountain Healthcare, Salt Lake City, UT, USA.
Mufaddal MamawalaBaylor Scott & White Health, Temple, TX, USA.
Nimish R ValviCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA.
Margaret M DunneWestat, Rockville, MD, USA.
Eric P GriggsCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Peter J EmbiCenter for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA.
Mark G ThompsonInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Ruth Link-GellesCoronavirus and Other Respiratory Viruses Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Mark W TenfordeInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Centers for Disease Control and Prevention · USWestat (United States) · USRegenstrief Institute · USIntermountain Healthcare · USBaylor Scott & White Health · USKaiser Permanente Center for Health Research · USScience Exchange (United States) · USBrigham Young University · USColumbia University Irving Medical Center · USHealthPartners · USKaiser Permanente · USMinnesota West Community & Technical College · USTemple College · USUniversity of Colorado Anschutz Medical Campus · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Understanding the usefulness of additional COVID-19 vaccine doses-particularly given varying disease incidence-is needed to support public health policy. We characterize the benefits of COVID-19 booster doses using number needed to vaccinate (NNV) to prevent one COVID-19-associated hospitalization or emergency department encounter. Methods: We conducted a retrospective cohort study of immunocompetent adults at five health systems in four U.S. states during SARS-CoV-2 Omicron BA.1 predominance (December 2021-February 2022). Included patients completed a primary mRNA COVID-19 vaccine series and were either eligible to or received a booster dose. NNV were estimated using hazard ratios for each outcome (hospitalization and emergency department encounters), with results stratified by three 25-day periods and site. Findings: 1,285,032 patients contributed 938 hospitalizations and 2076 emergency department encounters. 555,729 (43.2%) patients were aged 18-49 years, 363,299 (28.3%) 50-64 years, and 366,004 (28.5%) ≥65 years. Most patients were female (n = 765,728, 59.6%), White (n = 990,224, 77.1%), and non-Hispanic (n = 1,063,964, 82.8%). 37.2% of patients received a booster and 62.8% received only two doses. Median estimated NNV to prevent one hospitalization was 205 (range 44-615) and NNV was lower across study periods for adults aged ≥65 years (110, 46, and 88, respectively) and those with underlying medical conditions (163, 69, and 131, respectively). Median estimated NNV to prevent one emergency department encounter was 156 (range 75-592). Interpretation: The number of patients needed to receive a booster dose was highly dependent on local disease incidence, outcome severity, and patient risk factors for moderate-to-severe disease. Funding: Funding was provided by the Centers for Disease Control and Prevention though contract 75D30120C07986 to Westat, Inc. and contract 75D30120C07765 to Kaiser Foundation Hospitals.

Indexed as

BoostersCOVID-19HospitalizationmRNA vaccinesNumber needed to vaccinate

Identifiers

PMID37333688
PMCPMC10266334
OpenAlexW4380927205

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.